HUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer Treatment

The latest update is out from HUTCHMED (China) ( (HK:0013) ).

HUTCHMED (China) Limited announced significant findings from the SACHI Phase III study, which were presented at the 2025 ASCO Annual Meeting. The study demonstrated that the combination of savolitinib and osimertinib offers a significant progression-free survival benefit over chemotherapy for patients with EGFR mutation-positive non-small cell lung cancer with MET amplification. The combination therapy showed a favorable safety profile and has led to the acceptance of a New Drug Application by the China National Medical Products Administration, potentially impacting the treatment landscape for this patient population.

The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

More about HUTCHMED (China)

HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates primarily in China and has a strategic partnership with AstraZeneca for the marketing of its products.

YTD Price Performance: -0.44%

Average Trading Volume: 7,350,178

Technical Sentiment Signal: Sell

Current Market Cap: HK$19.57B

Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.